Physician profile
Alayna Mclean
NPI 1346702172
$1,606.97
in general payments reported to CMS, 2019-2025
29 companies · $14.50 in 2025
The $14.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.12 · 2020: $31.82 · 2021: $155 · 2022: $425 · 2023: $660 · 2024: $295 · 2025: $14.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.60 | 2022-2023 | Breztri, Farxiga, Evusheld |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.96 | 2021-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $139.39 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $98.50 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $90.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.13 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $60.81 | 2022-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $57.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $55.53 | 2023-2024 | |
| Pfizer INC. | $55.36 | 2019-2023 | |
| Seqirus USA INC | $52.38 | 2022-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Otsuka America Pharmaceutical, INC. | $48.95 | 2023-2024 | Rexulti |
| Mannkind Corporation | $45.87 | 2022-2023 | Afrezza |
| Amgen INC. | $43.17 | 2023-2024 | Otezla, Repatha |
| Cepheid | $42.03 | 2024 | Genexpert |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.07 | 2023 | Ofev |
| Daiichi Sankyo INC. | $22.84 | 2023 | Injectafer |
| Philips North America LLC | $22.51 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.74 | 2023 | |
| Novavax INC | $18.20 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Noven Therapeutics, LLC | $17.74 | 2023 | Xelstrym |
| Medtronic, INC. | $17.73 | 2022 | |
| Antares Pharma, INC. | $16.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.22 | 2022 | |
| Exact Sciences Corporation | $14.50 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $13.71 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.38 | 2023 | |
| Idorsia Pharmaceuticals US INC | $12.96 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alayna Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.